Emergence of a large-plaque variant in mice infected with coxsackievirus B3

mBio

Volumn 7, Issue 2, 2016, Pages

  Wang, Yao ^a   Pfeiffer, Julie K ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; AMINO ACID; CAPSID PROTEIN; GLYCAN; HEPARIN; POLYSACCHARIDE; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS INFECTION; COXSACKIEVIRUS B3; HELA CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER INJURY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS ATTACHMENT; VIRUS MUTANT; VIRUS PATHOGENESIS; VIRUS PLAQUE; VIRUS REPLICATION; VIRUS STRAIN; ADAPTATION; AMINO ACID SUBSTITUTION; ANIMAL; DISEASE MODEL; ENTEROVIRUS B; GENETICS; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; LIVER; METABOLISM; MISSENSE MUTATION; PATHOLOGY; VIRAL PLAQUE ASSAY; VIROLOGY; VIRULENCE;

ADAPTATION, BIOLOGICAL; AMINO ACID SUBSTITUTION; ANIMALS; CAPSID PROTEINS; COXSACKIEVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; ENTEROVIRUS B, HUMAN; HELA CELLS; HUMANS; LIVER; MICE; MUTATION, MISSENSE; POLYSACCHARIDES; PROTEIN BINDING; VIRAL PLAQUE ASSAY; VIRULENCE;

EID: 84965008222     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00119-16     Document Type: Article

References (55)

1. Tam PE. 2006. Coxsackievirus myocarditis: interplay between virus and host in the pathogenesis of heart disease. Viral Immunol 19:133–146. http://dx.doi.org/10.1089/vim.2006.19.133.
2. Tracy S, Höfling K, Pirruccello S, Lane PH, Reyna SM, Gauntt CJ. 2000. Group Bcoxsackievirus myocarditis and pancreatitis: connection between viral virulence phenotypes in mice. J Med Virol 62:70–81. http://dx.doi.org/10.1002/1096-9071(200009)62:1_70::AID-JMV11_3.0.CO;2-R.
3. Tracy S, Drescher KM. 2007. Coxsackievirus infections and NOD mice: relevant models of protection from, and induction of, type 1 diabetes. Ann N Y Acad Sci 1103:143–151. http://dx.doi.org/10.1196/annals.1394.009.
4. Tracy S, Drescher KM, Chapman NM, Kim KS, Carson SD, Pirruccello S, Lane PH, Romero JR, Leser JS. 2002. Toward testing the hypothesis that group B coxsackieviruses (CVB) trigger insulin-dependent diabetes: inoculating nonobese diabetic mice with CVB markedly lowers diabetes incidence. J Virol 76:12097–12111. http://dx.doi.org/10.1128/JVI.76.23.12097-12111.2002.
5. Chen P, Tao Z, Song Y, Liu G, Wang H, Liu Y, Song L, Li Y, Lin X, Cui N, Xu A. 2013. A coxsackievirus B5-associated aseptic meningitis outbreak in Shandong Province, China in 2009. J Med Virol 85:483–489. http://dx.doi.org/10.1002/jmv.23478.
6. Khetsuriani N, Lamonte-Fowlkes A, Oberst S, Pallansch MA, Centers for Disease Control and Prevention Centers for Disease and Prevention. 2006. Enterovirus surveillance—United States, 1970-2005. MMWR Surveill Summ 55:1–20. http://www.cdc.gov/mmwr/preview/mmwrhtml/ss5508a1.htm.
7. Muckelbauer JK, Kremer M, Minor I, Diana G, Dutko FJ, Groarke J, Pevear DC, Rossmann MG. 1995. The structure of coxsackievirus B3 at 3.5 Å resolution. Structure 3:653-667. http://dx.doi.org/10.1016/S0969-2126(01)00201-5.
8. Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, Horwitz MS, Crowell RL, Finberg RW. 1997. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320–1323. http://dx.doi.org/10.1126/science.275.5304.1320.
9. O’Shea C, Miyake-Stoner S, Powers C, Salk Institute for Biological Studies. 15 January 2015. Selective cell targeting using adenovirus and chemical dimers. U.S. Patent Application 14/485,472.
10. Coyne CB, Bergelson JM. 2006. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell 124: 119–131. http://dx.doi.org/10.1016/j.cell.2005.10.035.
11. Coyne CB, Bergelson JM. 2005. CAR: a virus receptor within the tight junction. Adv Drug Deliv Rev 57:869–882. http://dx.doi.org/10.1016/j.addr.2005.01.007.
12. Bergelson JM, Mohanty JG, Crowell RL, St John NF, Lublin DM, Finberg RW. 1995. Coxsackievirus B3 adapted to growth in RD cells binds to decay-accelerating factor (CD55). J Virol 69:1903–1906.
13. Carson SD, Chapman NM, Hafenstein S, Tracy S. 2011. Variations ofcoxsackievirus B3 capsid primary structure, ligands, and stability are selected for in a coxsackievirus and adenovirus receptor-limited environment. J Virol 85:3306–3314. http://dx.doi.org/10.1128/JVI.01827-10.
14. Carson SD, Kim KS, Pirruccello SJ, Tracy S, Chapman NM. 2007. Endogenous low-level expression of the coxsackievirus and adenovirus receptor enables coxsackievirus B3 infection of RD cells. J Gen Virol 88: 3031–3038. http://dx.doi.org/10.1099/vir.0.82710-0.
15. Milstone AM, Petrella J, Sanchez MD, Mahmud M, Whitbeck JC, Bergelson JM. 2005. Interaction with coxsackievirus and adenovirus receptor, but not with decay-accelerating factor (DAF), induces A-particle formation in a DAF-binding coxsackievirus B3 isolate. J Virol 79:655–660. http://dx.doi.org/10.1128/JVI.79.1.655-660.2005.
16. Pan J, Narayanan B, Shah S, Yoder JD, Cifuente JO, Hafenstein S, Bergelson JM. 2011. Single amino acid changes in the virus capsid permit coxsackievirus B3 to bind decay-accelerating factor. J Virol 85:7436–7443. http://dx.doi.org/10.1128/JVI.00503-11.
17. Powell RM, Ward T, Goodfellow I, Almond JW, Evans DJ. 1999. Mapping the binding domains on decay accelerating factor (DAF) for haemagglutinating enteroviruses: implications for the evolution of a DAFbinding phenotype. J Gen Virol 80:3145–3152. http://dx.doi.org/10.1099/0022-1317-80-12-3145.
18. Shafren DR, Williams DT, Barry RD. 1997. A decay-accelerating factorbinding strain of coxsackievirus B3 requires the coxsackievirusadenovirus receptor protein to mediate lytic infection of rhabdomyosarcoma cells. J Virol 71:9844–9848.
19. Zautner AE, Körner U, Henke A, Badorff C, Schmidtke M. 2003. Heparan sulfates and coxsackievirus-adenovirus receptor: each one mediates coxsackievirus B3 PD infection. J Virol 77:10071–10077. http://dx.doi.org/10.1128/JVI.77.18.10071-10077.2003.
20. Pfeiffer JK, Kirkegaard K. 2005. Increased fidelity reduces poliovirus fitness and virulence under selective pressure in mice. PLoS Pathog 1:e11. http://dx.doi.org/10.1371/journal.ppat.0010011.
21. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R. 2006. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439:344-348. http://dx.doi.org/10.1038/nature04388.
22. Coffey LL, Beeharry Y, Bordería AV, Blanc H, Vignuzzi M. 2011. Arbovirus high fidelity variant loses fitness in mosquitoes and mice. Proc Natl Acad Sci U S A 108:16038-16043. http://dx.doi.org/10.1073/pnas.1111650108.
23. Domingo E, Holland JJ. 1997. RNA virus mutations and fitness for survival. Annu Rev Microbiol 51:151–178. http://dx.doi.org/10.1146/annurev.micro.51.1.151.
24. Gnädig NF, Beaucourt S, Campagnola G, Bordería AV, Sanz-Ramos M, Gong P, Blanc H, Peersen OB, Vignuzzi M. 2012. Coxsackievirus B3 mutator strains are attenuated in vivo. Proc Natl Acad Sci U S A 109: E2294–E2303. http://dx.doi.org/10.1073/pnas.1204022109.
25. Graham RL, Becker MM, Eckerle LD, Bolles M, Denison MR, Baric RS. 2012. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat Med 18: 1820–1826. http://dx.doi.org/10.1073/pnas.1204022109.
26. Liu J, Thorp SC. 2002. Cell surface heparan sulfate and its roles in assisting viral infections. Med Res Rev 22:1–25. http://dx.doi.org/10.1002/med.1026.
27. Bernard KA, Klimstra WB, Johnston RE. 2000. Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology 276:93–103. http://dx.doi.org/10.1006/viro.2000.0546.
28. Klimstra WB, Ryman KD, Johnston RE. 1998. Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor. J Virol 72:7357–7366.
29. Sa-Carvalho D, Rieder E, Baxt B, Rodarte R, Tanuri A, Mason PW. 1997. Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J Virol 71: 5115–5123.
30. Kuss SK, Best GT, Etheredge CA, Pruijssers AJ, Frierson JM, Hooper LV, Dermody TS, Pfeiffer JK. 2011. Intestinal microbiota promote enteric virus replication and systemic pathogenesis. Science 334:249–252. http://dx.doi.org/10.1126/science.1211057.
31. Jones MK, Watanabe M, Zhu S, Graves CL, Keyes LR, Grau KR, Gonzalez-Hernandez MB, Iovine NM, Wobus CE, Vinjé J, Tibbetts SA, Wallet SM, Karst SM. 2014. Enteric bacteria promote human and mouse norovirus infection of B cells. Science 346:755–759. http://dx.doi.org/10.1126/science.1257147.
32. Kane M, Case LK, Kopaskie K, Kozlova A, MacDearmid C, Chervonsky AV, Golovkina TV. 2011. Successful transmission of a retrovirus depends on the commensal microbiota. Science 334:245–249. http://dx.doi.org/10.1126/science.1210718.
33. Kernbauer E, Ding Y, Cadwell K. 2014. An enteric virus can replace the beneficial function of commensal bacteria. Nature 516:94-98. http://dx.doi.org/10.1038/nature13960.
34. Baldridge MT, Nice TJ, McCune BT, Yokoyama CC, Kambal A, Wheadon M, Diamond MS, Ivanova Y, Artyomov M, Virgin HW. 2015. Commensal microbes and interferon-_ determine persistence of enteric murine norovirus infection. Science 347:266-269. http://dx.doi.org/10.1126/science.1258025.
35. Kanno T, Mackay D, Inoue T, Wilsden G, Yamakawa M, Yamazoe R, Murakami Y, Yamaguchi S, Shirai J, Kitching P, Murakami Y. 1999. Mapping the genetic determinants of pathogenicity and plaque phenotype in swine vesicular disease virus. J Virol 73:2710–2716.
36. Kandolf R, Hofschneider PH. 1985. Molecular cloning of the genome of a cardiotropic coxsackie B3 virus: full-length reverse-transcribed recombinant cDNA generates infectious virus in mammalian cells. Proc Natl Acad Sci U S A 82:4818–4822. http://dx.doi.org/10.1073/pnas.82.14.4818.
37. Yoder JD, Cifuente JO, Pan J, Bergelson JM, Hafenstein S. 2012. The crystal structure of a coxsackievirus B3-RD variant and a refined 9-angstrom cryoelectron microscopy reconstruction of the virus complexed with decayaccelerating factor(DAF)provide anewfootprint ofDAFonthe virus surface. J Virol 86:12571–12581. http://dx.doi.org/10.1128/JVI.01592-12.
38. Bordería AV, Isakov O, Moratorio G, Henningsson R, Agüera-González S, Organtini L, Gnädig NF, Blanc H, Alcover A, Hafenstein S, Fontes M, Shomron N, Vignuzzi M. 2015. Group selection and contribution of minority variants during virus adaptation determines virus fitness and phenotype. PLoS Pathog 11:e1004838. http://dx.doi.org/10.1371/journal.ppat.1004838.
39. Esko JD, Stewart TE, Taylor WH. 1985. Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc Natl Acad Sci U S A 82:3197–3201. http://dx.doi.org/10.1073/pnas.82.10.3197.
40. Esko JD, Weinke JL, Taylor WH, Ekborg G, Rodén L, Anantharamaiah G, Gawish A. 1987. Inhibition of chondroitin and heparan sulfate biosynthesis in Chinese hamster ovary cell mutants defective in galactosyltransferase I. J Biol Chem 262:12189–12195.
41. Silva LA, Khomandiak S, Ashbrook AW, Weller R, Heise MT, Morrison TE, Dermody TS. 2014. A single-amino-acid polymorphism in chikungunya virus E2 glycoprotein influences glycosaminoglycan utilization. J Virol 88:2385–2397. http://dx.doi.org/10.1128/JVI.03116-13.
42. Robinson CM, Jesudhasan PR, Pfeiffer JK. 2014. Bacterial lipopolysaccharide binding enhances virion stability and promotes environmental fitness of an enteric virus. Cell Host Microbe 15:36–46. http://dx.doi.org/10.1016/j.chom.2013.12.004.
43. Takemoto KK, Liebhaber H. 1961. Virus-polysaccharide interactions. I. An agar polysaccharide determining plaque morphology of EMC virus. Virology 14:456–462. http://dx.doi.org/10.1016/0042-6822(61)90338-5.
44. Wessely R, Klingel K, Knowlton KU, Kandolf R. 2001. Cardioselective infection with coxsackievirus B3 requires intact type I interferon signaling implications for mortality and early viral replication. Circulation 103: 756–761. http://dx.doi.org/10.1161/01.CIR.103.5.756.
45. Olofsson S, Bergström T. 2005. Glycoconjugate glycans as viral receptors. Ann Med 37:154–172. http://dx.doi.org/10.1080/07853890510007340.
46. Hileman RE, Fromm JR, Weiler JM, Linhardt RJ. 1998. Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays 20:156-167. http://dx.doi.org/10.1002/(SICI)1521-1878(199802)20:2_156::AID-BIES8_3.0.CO;2-R.
47. Prestwood TR, Prigozhin DM, Sharar KL, Zellweger RM, Shresta S. 2008. A mouse-passaged dengue virus strain with reduced affinity for heparan sulfate causes severe disease in mice by establishing increased systemic viral loads. J Virol 82:8411-8421. http://dx.doi.org/10.1128/JVI.00611-08.
48. Byrnes AP, Griffin DE. 2000. Large-plaque mutants of Sindbis virus show reduced binding to heparan sulfate, heightened viremia, and slower clearance from the circulation. J Virol 74:644–651. http://dx.doi.org/10.1128/JVI.74.2.644-651.2000.
49. Pfeiffer JK, Kirkegaard K. 2003. A single mutation in poliovirus RNAdependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci USA 100:7289–7294. http://dx.doi.org/10.1073/pnas.1232294100.
50. Kuss SK, Etheredge CA, Pfeiffer JK. 2008. Multiple host barriers restrict poliovirus trafficking in mice. PLoS Pathog 4:e1000082. http://dx.doi.org/10.1371/journal.ppat.1000082.
51. Muckelbauer JK, Kremer M, Minor I, Diana G, Dutko FJ, Groarke J, Pevear DC, Rossmann MG. 1995. The structure of coxsackievirus B3 at 3.5-Å resolution. Structure 3:653–667. http://dx.doi.org/10.1016/S0969-2126(01)00201-5.
52. Pei J, Kim BH, Grishin NV. 2008. PROMALS3D: a tool for multiple protein sequence and structure alignments. Nucleic Acids Res 36: 2295–2300. http://dx.doi.org/10.1093/nar/gkn072.
53. Mondor I, Ugolini S, Sattentau QJ. 1998. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans. J Virol 72:3623–3634.
54. Ida-Hosonuma M, Iwasaki T, Yoshikawa T, Nagata N, Sato Y, Sata T, Yoneyama M, Fujita T, Taya C, Yonekawa H, Koike S. 2005. The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. J Virol 79:4460-4469. http://dx.doi.org/10.1128/JVI.79.7.4460-4469.2005.
55. Lancaster KZ, Pfeiffer JK. 2010. Limited trafficking of a neurotropic virus through inefficient retrograde axonal transport and the type I interferon response. PLoS Pathog 6:e1000791. http://dx.doi.org/10.1371/journal.ppat.1000791.